Finzati - Logo
EXEL logo

Exelixis, Inc.

EXEL • Biotechnology
$59.01
▼ -0.12 (-0.20%)
Current price
EarningsLatest report: Jul 3, 2026
HIGHLY FAVORABLE PROFILEExcellentConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Strong business quality with supportive growth and cash-flow evidence. Valuation still matters, but the historical ratio profile is favorable.
Market Cap
$15.32B
Growth
12.2%
Cash Flow
5/5
Trend
Stable
Evidence
Stable or improving margins · 33.7%Positive revenue growth · 17.0%Positive free cash flow · 3.11Consistent free cash flow · 5/5Reasonable earnings multiple · 15.12
Financial data as of: Jul 3, 2026, 12:00 AM UTCLast earnings update: Jul 3, 2026, 12:00 AM UTCLast profile update: Aug 7, 2026, 12:28 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$59.01
Change-0.20%
Shares Out259.68M
Market Cap$15.32B
Enterprise Value$14.48B
52W Range33.76 - 57.57
Beta0.42
P/E17.81
P/S6.29
P/B8.31
P/FCF10.70
EV/Sales5.95

Investment DNA

How strong this company looks for long-term investors

87
out of 100
Business Quality
Margins, moat, returns
90/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
95/100
Price Attractiveness
Cheap or expensive today
71/100
Why this score▼
Stable or improving margins · 33.7%Positive revenue growth · 17.0%Positive free cash flow · 3.11Consistent free cash flow · 5/5Reasonable earnings multiple · 15.12Manageable debt level · 0.08

Analyst view

Analyst sentiment and price target

EXEL
Analyst sentiment
Based on 33 analyst votes · 2026-09-04
74/100
Bullish
Bullish
16
Hold
17
Bearish
0
Price Target
2026-08-07
Low
$44.00
Mean
$50.67
Median
$52.00
High
$56.00

Company Overview

IPO: 4/17/2000
Industry: Biotechnology
P/B i: 8.31
Debt / Equity i: 0.08
Operating Margin: 37.59%
Net Margin: 33.73%
ROE i: -
ROIC: -

Financial Health

Score15 / 20
Debt / Equity: 0.08
Current Ratio: 3.56
Quick Ratio: 3.50
Status: Good

Insider Transactions

Recent executive and insider activity

⚠ 1 high-volume insider sell detected
Eckhardt Sue Gail
Transaction: 06/01/2026
SELL
Change
-9,812
Price
$50.14
Filing
06/03/2026
Type
SELL
WYSZOMIERSKI JACK L
Transaction: 06/01/2026
SELL
Change
-3,925
Price
$50.55
Filing
06/03/2026
Type
SELL
JOHNSON DAVID EDWARD
Transaction: 05/27/2026
BUY
Change
+19,133
Price
$50.03
Filing
05/29/2026
Type
BUY